

EFFICACY OF LEVOFLOXACIN IN COMPLEX TREATMENT OF PATIENTS WITH MULTIDRUG-RESISTANT TUBERCULOSIS AND EXTENSIVE DRUG-RESISTANT TUBERCULOSIS

***S. O. Cherenko, N. A. Litvinenko, M. V. Pogrebnaya,
V. V. Davidenko, U. O. Senko***

Summary

A comparative analysis of efficacy of levofloxacin (Levolet, Dr Reddy's Laboratories Ltd) and ofloxacin in complex treatment of 60 patients with multidrug-resistant tuberculosis and extensive drug-resistant tuberculosis have been conducted. Higher efficacy of levofloxacin have been revealed: sputum conversion have been observed in 46,7 % of patients (in ofloxacin group — in 20 %, $p < 0,05$). This meant that number of infectious cases of tuberculosis (major public health threat) decreased by 26,7 %. The rate of adverse reactions was 50 % in both regimens, whereas in levofloxacin group drug-related side effects were noted in 16,7 % of patients to the contrast of ofloxacin group — 43,3 % ($p < 0,05$). Thus, levofloxacin is an effective 2nd line fluoroquinolone anti-tuberculous drug with good safety profile.